Eagle Pharmaceuticals investor relations material

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. It primarily offers Ryanodex, an intravenous formulation of dantrolene sodium used for treating patients in various malignant hyperthermia crises. The company also develops Bendeka, a once-daily intravenous formulation of bendamustine hydrochloride that is in late-stage development for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma.